Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.
Neurodegener Dis Manag
; 8(3): 161-170, 2018 06.
Article
em En
| MEDLINE
| ID: mdl-29633651
ABSTRACT
AIM:
To determine if age and Parkinson's disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living. PATIENTS &METHODS:
This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of 'off' time and levodopa equivalent dose. Patients' data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG. RESULTS &CONCLUSION:
LCIG therapy led to sustained improvements in quality of life irrespective of patient age and disease duration at baseline. Improvements in activities of daily living were observed across all subgroups, particularly in younger patients, patients with shorter disease duration and in patients with the highest baseline levodopa equivalent dose.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Qualidade de Vida
/
Atividades Cotidianas
/
Carbidopa
/
Levodopa
/
Intestinos
/
Antiparkinsonianos
Tipo de estudo:
Qualitative_research
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Neurodegener Dis Manag
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Itália